Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

GP-2250

Phase 1Small molecule

GGeistlich Pharma AG

GP-2250 is one of 49 small molecule programs targeting Ovarian Cancer. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

48

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ovarian CancerRecruiting

Ovarian CancerPhase 1

Recruiting

Competition

Competitive Landscape

207 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Hycamtin

Pegylated Liposomal Doxorubicin

Adriamycin

Lynparza

RRisen (Suzhou) Pharma Tech Co., Ltd.

Zepzelca

Jazz Pharmaceuticals

Afinitor

Neulasta

Taxotere

Elahere

IImmunogenics, LLC

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Ovarian Cancer

NCT03854110

Clinical

Trials by Indication[1]

Ovarian Cancer1 trial

A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine in Subjects With Advanced Solid Tumors

Recruiting·GGeistlich Pharma AG·Phase 1·NCT03854110·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GP-2250. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GP-2250 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GP-2250. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Geistlich Pharma AG company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: GGeistlich Pharma AG

Related News